Biogen

News

Novartis takes aim at MS blockbuster Tysabri in US and Europ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year.

News

Polpharma in pole position for biosimilar Tysabri in Europe

Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version of Biogen's blockbuster multiple sclerosis therapy

News

Eisai/Biogen could get FDA verdict on new Alzheimer's drug b...

The FDA has started an accelerated review of Eisai and Biogen's a new amyloid-targeting antibody lecanemab for Alzheimer's disease, with a 6 January deadline that keep them ahead of closest

News

Liver injuries prompt clinical hold on Sanofi BTK drug

One of the main assets of Sanofi's $3.7 billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated.

News

Biogen and Happify partner on digital support for MS patient...

Digital health company Happify has signed a partnership with another biopharma company, joining forces with Biogen on a toolkit to help people with

News

Biogen waves bye to $217m ALS partnership with Karyopharm

Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease amyotrophic lateral sclerosis that could have been worth up to $

Novartis takes aim at MS blockbuster Tysabri in US and Europ...

Polpharma in pole position for biosimilar Tysabri in Europe

Eisai/Biogen could get FDA verdict on new Alzheimer's drug b...

Liver injuries prompt clinical hold on Sanofi BTK drug

Biogen and Happify partner on digital support for MS patient...

Biogen waves bye to $217m ALS partnership with Karyopharm

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Biogen

Editor's Picks